SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is trending following a $1 billion Pentagon investment in its missile business and an announced plan to spin off the unit as a standalone, publicly traded company in late 2026. While some investors view the spinoff as a strategic way to unlock value and scale manufacturing, the stock is seeing significant volatility as traders debate the long-term impact on the core business and current valuation.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending due to bullish sentiment surrounding its role as a key infrastructure provider for AI data centers, with investors highlighting the company's strong growth and its recent addition to the S&P 100. Traders are actively discussing the stock's positive price action and momentum as it approaches all-time highs, though some remain cautious, debating the sustainability of its current valuation and the potential for a pullback.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Investors are focused on Rezolve AI's integration and ownership of the Subsquid (SQD) decentralized data infrastructure, frequently citing partnerships with major entities like Google Cloud and Robinhood as key drivers for long-term utility and adoption. While bulls emphasize the potential for massive infrastructure revenue and network growth, a segment of the community remains skeptical, questioning the token's direct monetization value and labeling previous price volatility as a pump-and-dump cycle.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing a significant stock price decline, with traders debating whether the selling pressure is driven by institutional manipulation, recent insider selling, or a correction following a speculative pre-earnings rally. While some investors view the current price as an attractive entry point for a long-term turnaround, others are concerned about the stock's continued downward momentum and lack of immediate catalysts.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

DUOT is trending as traders focus on the company's strategic pivot toward AI infrastructure and modular edge data centers, bolstered by recent capital inflows and growth in contracted AI hosting capacity. While some investors express concern over potential dilution to fund infrastructure builds, bullish sentiment is driven by the company's contracted revenue pipeline and its ability to rapidly deploy compute capacity compared to hyperscale competitors.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie shares are trending as the company navigates the $10.9 billion acquisition of Apogee Therapeutics to bolster its immunology pipeline and continues to see strong performance from its core growth drivers, Skyrizi and Rinvoq. Investors are actively debating the company's valuation, dividend stability, and strategic M&A approach, while also monitoring competitive threats within its key therapeutic areas.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to community discussions regarding its acquisition strategy, specifically the $7.8 billion deal for Arcellx to bolster its CAR-T cell therapy pipeline. Traders are also actively analyzing the company's Q4 financial results, dividend increase, and competitive outlook for its HIV and oncology franchises.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending due to a sharp sympathy sell-off triggered by a failed Phase 3 trial of a competitor's cholesterol drug, despite market commentary noting the company's distinct mechanism and robust underlying fundamentals. While some investors are concerned about potential read-through risks to its own pipeline, many traders view the price decline as an overreaction and a buying opportunity.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as traders debate the potential impact of GameStop's ongoing pursuit of a takeover or strategic partnership, with many discussing the uncertainty surrounding the deal and the recent increase in GameStop's stake in the company. Community sentiment remains polarized, characterized by a mix of speculation regarding the deal's feasibility and concerns over eBay's management and future direction.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The community discussion is fragmented, characterized by a mix of political commentary regarding the upcoming election cycle, speculation on geopolitical tensions in the Middle East, and varied technical analysis of broader market direction and inflation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences is trending as traders discuss its ongoing pipeline expansion, particularly in oncology and HIV, alongside speculation about potential future acquisitions and reactions to recent earnings. Investors are balancing optimism over the company's long-term commercial strategy with frustration over the stock's relatively steady performance compared to broader market gains.

If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market capitalization ofread more...

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?

Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the worlds most challenging diseases. The new...

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Key PointsGilead is best known for its dominant HIV franchise...

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?

Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.

Top Research Reports for Toyota Motor, CrowdStrike & Welltower

Toyota Motor's hybrid growth and expanded value-chain businesses support demand, but higher costs, China weakness and leverage temper prospects.

Can Bixlenvo Unlock New Growth for Gilead's HIV Business?

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict  

Equity

Bearish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

GILD Gilead Sciences, Inc.

Fundamentals

Latest GILD News